Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Sep;42(9):3537-3539.
doi: 10.1007/s10072-021-05427-4. Epub 2021 Jun 29.

Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19

Affiliations
Case Reports

Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19

Shuai Chen et al. Neurol Sci. 2021 Sep.

Abstract

With recent availability of COVID-19 vaccine, post-vaccination neurological complications had been occasionally reported. Here, we reported for the first time a case of neuromyelitis optica spectrum disorder (NMOSD) that developed after the first dose of inactivated virus vaccine for COVID-19. The patient developed mild fever, vomiting, diarrhea, and cough after receiving the first dose of inactivated virus vaccine. Two months later, she experienced dizziness and unsteady walking. MRI scanning of the brain revealed lesions in area postrema and bilateral hypothalamus, typical for NMOSD. Serum antibodies for AQP4, ANA, SSA, SSB, Ro-52, and p-ANCA were positive. The patient was diagnosed as AQP4-positive NMOSD with coexisting systemic autoimmunity. After treatment with methylprednisolone (500 mg for 5 days), symptoms were greatly relieved. As NMOSD is seriously harmful and curative, it is important to be aware of the NMOSD symptoms after vaccination. Cautions should be given for those with preexisting systemic autoimmune abnormalities in vaccination for COVID-19.

Keywords: AQP4; Autoimmune response; COVID-19; NMOSD; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Brain MRI of the patient. AC showed area postrema and bilateral hypothalamus lesions on fluid-attenuated inversion recovery (FLAIR) sequence. D showed area postrema lesion on sagittal T2-weighted sequence

References

    1. Ghosh R, De K, Roy D, et al. A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection. J Neuroimmunol. 2020;350:577439. doi: 10.1016/j.jneuroim.2020.577439. - DOI - PMC - PubMed
    1. de Ruijter NS, Kramer G, Gons RAR, et al. Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report. Mult Scler Relat Disord. 2020;46:102474. doi: 10.1016/j.msard.2020.102474. - DOI - PMC - PubMed
    1. Batum M, KisabayAk A, Mavioğlu H. Covid-19 infection-induced neuromyelitis optica: a case report. Int J Neurosci. 2020;30:1–7. - PubMed
    1. Goss AL, Samudralwar RD, Das RR, et al. ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol. 2021 doi: 10.1002/ana.26065. - DOI - PMC - PubMed
    1. Vlachoyiannopoulos G, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely-ill patients with COVID-19. Ann Rheum Dis. 2021;79(12):1661–1663. doi: 10.1136/annrheumdis-2020-218009. - DOI - PubMed

Publication types